Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhProuk vs alteplase in acute STEMI
CTR20260238Phase 3Active
- Sponsor
- Landing Biological Pharmaceutical
- Start
- Mar 2026
- Modality
- Metabolic Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of recombinant human prourokinase in myocardial infarction (MI) (2 arms), sponsored by Landing Biological Pharmaceutical. Primary endpoint: Infarct-related artery patency rate by coronary angiography at 90–180 minutes after start of thrombolytic therapy. Started Mar 2026; status: active.
02
Drugs
recombinant human prourokinase
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on CTR20260238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260238.